Related Experiment Video

Updated: Sep 20, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated

Jørn Henriksen1, Trude H Aagesen, Gunhild M Maelandsmo

  • 1Department of Tumour Biology, Institute of Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway.

Oncogene
|August 15, 2003
PubMed

Insights

In osteosarcomas, COPS3 amplification is more common than MDM2 amplification and often inactivates the TP53 tumor suppressor pathway. This suggests proteasome pathway aberrations contribute to cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The TP53 tumor suppressor pathway is crucial in preventing cancer.
  • Alterations in TP53, such as mutations or MDM2 amplification, are common in sarcomas.
  • However, many osteosarcomas lack these typical aberrations, indicating other mechanisms are involved.

Purpose of the Study:

  • To investigate the role of COPS3, a proteasome pathway component, in osteosarcoma development.
  • To analyze the frequency of COPS3 amplification in osteosarcomas compared to MDM2 amplification.
  • To determine the relationship between COPS3 amplification, MDM2 amplification, and TP53 mutations in osteosarcoma.

Main Methods:

  • Analysis of TP53 mutations in osteosarcoma samples.
  • Measurement of MDM2 and COPS3 expression levels.
  • Genetic analysis to detect amplifications of MDM2 and COPS3.
  • Correlation of genetic alterations with TP53 pathway status.

Main Results:

  • COPS3 amplification was found more frequently in osteosarcomas than MDM2 amplification.
  • Tumors with COPS3 amplification did not exhibit MDM2 amplification or TP53 mutations.
  • These findings support the hypothesis that alterations in TP53, MDM2, or COPS3 are often mutually exclusive, with one aberration being sufficient.
  • Inactivation of TP53 by proteasome pathway aberrations may contribute to osteosarcoma aneuploidy.

Conclusions:

  • COPS3 amplification represents an alternative mechanism for TP53 pathway inactivation in osteosarcoma.
  • Aberrations in the proteasome pathway, specifically COPS3 amplification, play a significant role in osteosarcoma pathogenesis.
  • Targeting the proteasome pathway could be a potential therapeutic strategy for osteosarcomas with intact TP53.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...